- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer
Neal Shore, MD, FACS, discusses how the SunRISe-1 trial design addresses the need for bladder-sparing treatment options for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (HR NMIBC) who are ineligible for or refuse radical cystectomy. He also contrasts the treatment approach and outcomes observed in the NURE-COMBO trial with the current standard neoadjuvant chemotherapy plus radical cystectomy regimen for muscle-invasive bladder cancer (MIBC), discussing how this chemoimmunotherapy combination may potentially expand treatment options for this patient population.
EP: 1.Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC
EP: 2.SunRISe-1: Examining Combination Therapy for HR NMIBC
EP: 3.NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC
EP: 4.Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC
EP: 5.SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer
EP: 6.Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations
EP: 7.Final Insights on Current Bladder Cancer Clinical Trials
Video content above is prompted by the following question(s):
- How does the SunRISe-1 trial design address the need for bladder-sparing treatment options for patients with BCG-unresponsive HR NMIBC who are ineligible or refuse radical cystectomy? Discuss the rationale for investigating the combination of TAR-200 and cetrelimab, as well as the TAR-200 and cetrelimab monotherapy approaches, in this patient population and how the preliminary results from the combination cohort compare to the monotherapy cohorts.
- Contrast the treatment approach and outcomes observed in the NURE-COMBO trial with the current standard neoadjuvant chemotherapy plus radical cystectomy regimen for MIBC. How might this chemoimmunotherapy combination potentially expand treatment options for this patient population?
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
